Search Results

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will present at the William Blair 44th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 4, 2024 at 8:00 AM CT.

West Pharmaceutical Services, Inc. announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will present at the Bank of America Securities Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2024, at 11:20 AM PT.

Imagine Pharma, a biotech company focused on advancing the commercialization of its novel IMG-1 polypeptide in Oral Delivery, Therapeutics, and Regenerative Medicine, announced that the West Virginia University Health System, which operates under the brand WVU Medicine, has awarded a contract to the Company to provide human clinical islet isolation services for patients undergoing a total pancreatectomy and autologous islet cell transplant.

Alcami Corporation announced it has completed the acquisition of Pacific Pharmaceutical Services, Inc., a preferred provider of cGMP pharma storage and services.

West Pharmaceutical Services, Inc. announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West Pharmaceutical Services, Inc. announced that it will unveil its new Daikyo Crystal Zenith® Nested Vials in Tub at the International Society for Cell and Gene Therapy Annual Meeting taking place in Vancouver, Canada from May 29- June 1.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a second-quarter 2024 dividend of $0.20 per share.

West Pharmaceutical Services, Inc. announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance.